Engineering the gut microbiota to treat chronic diseases

被引:0
作者
Noura S. Dosoky
Linda S. May-Zhang
Sean S. Davies
机构
[1] Vanderbilt University,Department of Pharmacology and Division of Clinical Pharmacology
来源
Applied Microbiology and Biotechnology | 2020年 / 104卷
关键词
Gut microbiota; Engineered bacteria; Cancer; Diabetes; Inflammatory bowel disease; Atherosclerosis; Obesity;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:7657 / 7671
页数:14
相关论文
共 804 条
[81]  
Buffa V(2013)Systemic administration of attenuated J Drug Target 21 528-789
[82]  
Stieh D(2001) carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model Anticancer Res 21 857-522
[83]  
Mamhood N(2015)Bacterial-directed enzyme prodrug therapy Curr Opin Biotechnol 35 94-275
[84]  
Hu Q(2013)Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment Trends Endocrinol Metab 24 332-5039
[85]  
Fletcher P(2005)Identification of tumor-specific Proc Natl Acad Sci U S A 102 11993-3462
[86]  
Shattock RJ(2017) promoters and their regulatory logic Genome Res 27 289-297
[87]  
Caluwaerts S(2013) as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth J Autoimmun 40 45-152
[88]  
Vandenbroucke K(2014)A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer Diabetes 63 2876-541
[89]  
Steidler L(2016)Retraction: a genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer Nat Rev Immunol 16 341-95
[90]  
Neirynck S(2002)Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy J Immunother 25 218-399